Key Highlights

  • Net sales grew 7% to USD 390.8 million in the fiscal first quarter ended September 30, 2026, a 5% sequential increase, and organic growth reached 3% across every vertical.
  • Diluted EPS dropped to USD 0.11 from USD 0.40, while adjusted diluted EPS came in at USD 0.25 versus USD 0.49 after a higher tax charge and greater selling costs.
  • Medical sales rose 14% to USD 115.7 million, including 9% organic growth, with the recently acquired Helvoet Polymer Technologies contributing to the result.
  • Fiscal 2027 guidance was reaffirmed, and the company now expects net sales at the upper end of its USD 1,535 million to USD 1,560 million range.

Top-Line Recovery Led by Medical and the Helvoet Deal

Kimball Electronics (NASDAQ:KE) announced fiscal first-quarter 2027 results on November 4, 2026. Net sales moved up from USD 365.6 million to USD 390.8 million, with Automotive rising 4% to USD 170.5 million, Industrial climbing 5% to USD 104.6 million and Medical jumping 14%. The Business provides electronics Manufacturing services and contract development and manufacturing for medical clients from plants in the United States, China, India, Mexico, Europe and Thailand. The CEO described organic growth as in line with expectations, powered by a high single-digit rise in Medical. Helvoet Polymer Technologies, a recent tuck-in, added to the reported gain, and sales increased 5% from the prior quarter. Automotive still accounts for the largest share at 44% of sales, ahead of Medical at 29% and Industrial at 27%.

Why Profit Slipped Even Though Sales Expanded

Gross Margin held at 7.9% of sales, yet selling and administrative spending increased to USD 18.1 million, or 4.6% of sales, from USD 13.1 million, or 3.5%. Operating Income declined to USD 12.4 million from USD 14.5 million, leaving a 3.2% margin against 4.0%. The adjusted Operating Margin came in at 4.3% versus 4.8%. Interest expense rose to USD 3.5 million, and the tax provision reached USD 5.2 million on pretax income of USD 7.8 million, an effective rate of about 66% (calculated). Net Income fell to USD 2.6 million from USD 10.1 million, and the release does not explain the tax rate.

Cash Outflow, Heavier Debt and Guidance Near the Top of the Range

Operating activities consumed USD 19.3 million of cash, compared with USD 8.1 million generated a year earlier, while investing used USD 109.7 million and financing supplied USD 114.0 million. Debt reached USD 235.7 million against cash of USD 72.8 million, and borrowing capacity stood at USD 198.0 million. The company bought back 127,000 shares for USD 3.1 million. Cash conversion days came in at 82, a multiyear low. Guidance also points to adjusted operating income of 4.4% to 4.7% of sales and Capital spending of USD 50 million to USD 60 million, with the call scheduled for November 5, 2026.

Where Things Stand

No, not this quarter. Sales grew, but profit did not follow. Kimball Electronics (NASDAQ:KE) returned to 7% top-line growth, helped by Helvoet and 14% Medical growth, while GAAP EPS fell to USD 0.11 on higher selling costs, interest and taxes. Guidance was reaffirmed with sales at the upper end of the range, though the adjusted margin of 4.3% still needs to rise to reach the 4.4% to 4.7% target. Watch cash generation, the integration of Helvoet and the November 5 call.